Alnylam
Unicorn Β· $31.2BFounded 2002 Β· 3,026 employees on LinkedIn Β· 4 known investors
Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
Also known as ALNY Β· Alnylam Pharmaceuticals Β· Alnylam Pharmaceuticals, Inc.
Founders & leadership
Alnylam was founded in 2002 by John Maraganore.
Investors Β· 4
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed β not independently audited.
Founder mafia
2 people who came through Alnylam went on to found or lead other companies.
Competitors Β· 1
by search overlap
Companies competing with Alnylam for the same Google search keywords, organic and paid, via search-intersection analysis.
Timeline Β· 38
launches, deals, and filingsInvestment adds new capacity and enzymatic ligation manufacturing capability to meet demand for RNAi therapeutics.
$250M source β
Roche partnered with Alnylam in a deal worth $2.8 billion for the development of a hypertension drug.
$2.8B source β
Novartis announced FDA approval of Leqvio, an siRNA therapy to lower LDL cholesterol; Novartis holds global rights under a license and collaboration agreement with Alnylam.
Application to initiate a Phase 1 study of ALN-APP, an RNAi therapeutic targeting amyloid precursor protein for Alzheimer's disease and cerebral amyloid angiopathy.
Maraganore announced he would step down as CEO, succeeded by COO Yvonne Greenstreet effective January 1, 2022.
Former Sanofi CEO joins Alnylam's board.
First approved RNAi therapeutic in a prevalent disease; licensed to Novartis.
Former U.S. FDA Commissioner (May 2009-April 2015) joins Alnylam's board.
First-ever approved RNAi therapeutic and Alnylam's first commercial medicine; US approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis.
The Phase III trial of lead product revusiran was halted due to increased deaths in the drug arm; the company terminated development of the compound.
Alnylam purchased Merck & Co.'s Sirna Therapeutics for $25 million cash and $150 million in stock.
$175M source β
Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million.
$700M source β
Collaboration to develop a drug to treat a genetic form of high cholesterol.
Alnylam licensed Arbutus's lipid nanoparticle technology, used to deliver patisiran to the liver.
Alliance to develop biotech solutions for the farming industry by developing natural molecules for crop protection.
Collaboration to develop RNAi technology enhancing vaccine production.
After Novartis declined to expand its $100 million option for nonexclusive rights and Roche dropped its investment, Alnylam let 25% of its workforce go.
Alliances to market a drug targeted at respiratory syncytial virus.
Alnylam partnered with Ionis Pharmaceuticals to found Regulus Therapeutics, focused on microRNA therapeutics.
Alnylam received $331 million in exchange for access to its RNAi technology platform.
$331M source β
Collaboration to develop treatments for progressive multifocal leukoencephalopathy.
Collaboration to develop drug-device combinations to treat neurodegenerative disorders.
Alnylam filed for an IPO on February 27, 2004, raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
$26M source β
Alnylam merged with German pharmaceutical company Ribopharma AG; the newly formed company also received $24.6 million in funding from private-equity firms.
Founded on June 14, 2002 by Phillip Sharp, David Bartel, Thomas Tuschl, Paul Schimmel and Phillip Zamore, with investors Christoph Westphal and John Kennedy Clarke; John Maraganore was founding CEO. The company was a spin-off from the Max Planck Institute for Biophysical Chemistry and was named after the star Alnilam.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
Morgan Stanley Raises its Price Target on Alnylam (ALNY) - Insider Monkeyinsidermonkey.com Β· Jul 2026
ALNY Stock Rallies As RNAi Expansion And AI Deals Deepen - StocksToTradestockstotrade.com Β· Jul 2026βΈResearch sources Β· 8
primary sources listed
- Alnylamalnylam.com Β· web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Alnylam do?
- Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.
- Who founded Alnylam?
- Alnylam was founded by John Maraganore in 2002.
- Who are Alnylam's investors?
- Alnylam's investors include ARCH Venture Partners, Atlas Venture, Blackstone Life Sciences, Cardinal Partners.